DarioHealth Statistics
Total Valuation
DarioHealth has a market cap or net worth of $51.41 million. The enterprise value is $63.21 million.
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DarioHealth has 7.31 million shares outstanding. The number of shares has increased by 92.70% in one year.
| Current Share Class | 7.31M |
| Shares Outstanding | 7.31M |
| Shares Change (YoY) | +92.70% |
| Shares Change (QoQ) | -16.79% |
| Owned by Insiders (%) | 19.97% |
| Owned by Institutions (%) | 5.81% |
| Float | 5.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.43 |
| Forward PS | 1.78 |
| PB Ratio | 0.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.07, with a Debt / Equity ratio of 0.51.
| Current Ratio | 3.07 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.29 |
Financial Efficiency
Return on equity (ROE) is -59.87% and return on invested capital (ROIC) is -21.79%.
| Return on Equity (ROE) | -59.87% |
| Return on Assets (ROA) | -19.73% |
| Return on Invested Capital (ROIC) | -21.79% |
| Return on Capital Employed (ROCE) | -36.79% |
| Weighted Average Cost of Capital (WACC) | 10.25% |
| Revenue Per Employee | $128,430 |
| Profits Per Employee | -$253,116 |
| Employee Count | 165 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.87 |
Taxes
In the past 12 months, DarioHealth has paid $140,000 in taxes.
| Income Tax | 140,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.22% in the last 52 weeks. The beta is 1.08, so DarioHealth's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -50.22% |
| 50-Day Moving Average | 7.47 |
| 200-Day Moving Average | 10.34 |
| Relative Strength Index (RSI) | 48.31 |
| Average Volume (20 Days) | 10,354 |
Short Selling Information
The latest short interest is 79,728, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 79,728 |
| Short Previous Month | 70,660 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.52% |
| Short Ratio (days to cover) | 11.54 |
Income Statement
In the last 12 months, DarioHealth had revenue of $21.19 million and -$41.76 million in losses. Loss per share was -$8.29.
| Revenue | 21.19M |
| Gross Profit | 12.96M |
| Operating Income | -34.56M |
| Pretax Income | -40.60M |
| Net Income | -41.76M |
| EBITDA | -32.15M |
| EBIT | -34.56M |
| Loss Per Share | -$8.29 |
Full Income StatementBalance Sheet
The company has $20.01 million in cash and $31.82 million in debt, giving a net cash position of -$11.80 million or -$1.61 per share.
| Cash & Cash Equivalents | 20.01M |
| Total Debt | 31.82M |
| Net Cash | -11.80M |
| Net Cash Per Share | -$1.61 |
| Equity (Book Value) | 62.38M |
| Book Value Per Share | 8.55 |
| Working Capital | 19.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$25.29 million and capital expenditures -$142,000, giving a free cash flow of -$25.44 million.
| Operating Cash Flow | -25.29M |
| Capital Expenditures | -142,000 |
| Depreciation & Amortization | 2.41M |
| Net Borrowing | 185,000 |
| Free Cash Flow | -25.44M |
| FCF Per Share | -$3.48 |
Full Cash Flow StatementMargins
Gross margin is 61.13%, with operating and profit margins of -163.06% and -192.23%.
| Gross Margin | 61.13% |
| Operating Margin | -163.06% |
| Pretax Margin | -191.57% |
| Profit Margin | -192.23% |
| EBITDA Margin | -151.71% |
| EBIT Margin | -163.06% |
| FCF Margin | n/a |
Dividends & Yields
DarioHealth does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -92.70% |
| Shareholder Yield | -92.70% |
| Earnings Yield | -81.24% |
| FCF Yield | -49.48% |
Analyst Forecast
The average price target for DarioHealth is $18.50, which is 166.96% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.50 |
| Price Target Difference | 166.96% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 33.56% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on August 28, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Aug 28, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
DarioHealth has an Altman Z-Score of -6.13 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.13 |
| Piotroski F-Score | 2 |